This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
GEHC Stock Gains on Long-Term Collaboration With Sutter Health
by Zacks Equity Research
GE HealthCare announces a seven-year strategic collaboration with Sutter Health.
Cardinal Health Stock May Gain With New Texas Distribution Center
by Zacks Equity Research
CAH announces the ongoing construction of a new distribution center in Texas, which is likely to support its at-Home Solutions business.
Intuitive Surgical Stock Surges on Q4 Preliminary Revenue Beat
by Zacks Equity Research
ISRG records significant growth in the top line, driven by higher system placements as well as improved pricing. Procedure volume remains strong.
PACB Stock Declines Despite Promising HiFi Sequencing Findings
by Zacks Equity Research
PacBio announces positive study results for HiFi long-read sequencing technology in identifying genetic causes of rare diseases.
PACB Stock Falls on Preliminary Q4 Sales Miss, 7 Vega Systems Shipped
by Zacks Equity Research
PacBio reports dismal preliminary fourth-quarter 2024 results, caused by lower instrument. New launches and clinical focus set the stage for market growth in 2025.
GKOS Stock Gains Following Positive Study Data on iDose Platform
by Zacks Equity Research
Glaukos' iDose TR achieves lasting IOP reduction and safety, transforming glaucoma treatment. The company is progressing well with its next-generation iDose TREX.
ARAY Stock Gains as China Approves Latest Radiation Therapy Solutions
by Zacks Equity Research
Accuray announces the approval of the Chinese NMPA for its latest radiation therapy solutions.
DexCom Stock Up Following Strong Preliminary Q4 Results & 2025 Outlook
by Zacks Equity Research
DXCM's top line reflects strong demand for its CGM sensors. International expansion is also driving sales higher. Gross margin reflects inventory damage.
TEM Stock Declines Following Preliminary Q4 Sales Miss
by Zacks Equity Research
Tempus reports strong 2024 growth and unveils a bold 2025 outlook with 75% revenue growth and innovative diagnostics.
PacBio Stock May Gain Following the Collaborated Launch of GutID
by Zacks Equity Research
PACB and Intus Bio collaborate to launch GutID, the first commercial human gut health test.
Here's Why You Should Retain DexCom Stock in Your Portfolio for Now
by Zacks Equity Research
DXCM continues to raise optimism among investors owing to its strong product portfolio.
Are Medical Stocks Lagging Aptevo Therapeutics (APVO) This Year?
by Zacks Equity Research
Here is how Aptevo Therapeutics Inc. (APVO) and Accuray (ARAY) have performed compared to their sector so far this year.
PACB Stock Rises After the Shipment of Vega Systems to Berry Genomics
by Zacks Equity Research
PacBio delivers the first Vega systems to Berry Genomics to develop and optimize its targeted assays to support screening programs in China and other markets.
Tempus AI Stock Falls Despite Collaboration Announcement With Genialis
by Zacks Equity Research
TEM announces a collaboration with Genialis to develop new RNA-based algorithms across cancer types.
Here's Why You Should Retain OPKO Health Stock in Your Portfolio
by Zacks Equity Research
OPK's growth is fueled by Rayaldee's success and accelerated clinical trials. However, stiff competition and overdependence on its lead product are concerns.
Here's Why You Should Add Accuray Stock to Your Portfolio Now
by Zacks Equity Research
ARAY's solid product demand and revenue growth raise optimism about the stock.
BDSX Stock Rises After Publication of Study Data for Nodify CDT Test
by Zacks Equity Research
Biodesix announces positive study data for its Nodify CDT blood-based lung nodule test published in CHEST Pulmonary Journal.
Stryker Stock Falls Despite the Agreement to Acquire Inari Medical
by Zacks Equity Research
SYK inks an agreement to acquire Inari Medical at a valuation of approximately $4.9 billion.
Here's Why You Should Retain BDX Stock in Your Portfolio for Now
by Zacks Equity Research
BD's robust product portfolio and a few strategic deals raise optimism about the stock. However, stiff competition and macroeconomic volatility are concerns.
TMCI Stock May Gain From the Limited Release of the Percuplasty System
by Zacks Equity Research
Treace Medical announces the limited market release of the Percuplasty Percutaneous 3D Bunion Correction System, targeting the in-demand bunion surgery market.
Cencora Stock May Gain Following the Strategic Acquisition of RCA
by Zacks Equity Research
COR completes the acquisition of Retina Consultants of America, marking a significant step in expanding its specialty healthcare and MSO solutions.
Reasons to Add Cardinal Health Stock to Your Portfolio Now
by Zacks Equity Research
CAH continues to grow on the back of its robust product portfolio and a strong quarterly result.
Here Is Why Bargain Hunters Would Love Fast-paced Mover Accuray (ARAY)
by Zacks Equity Research
If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Accuray (ARAY) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen.
Here's Why You Should Add MMSI Stock to Your Portfolio Now
by Zacks Equity Research
Merit Medical's strong product portfolio raises optimism about the stock.
Inogen Stock Rises as FDA Clears SIMEOX 200 Airway Clearance Device
by Zacks Equity Research
INGN announces FDA clearance for the SIMEOX 200 Airway Clearance Device.